724471-16-3Relevant articles and documents
THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS
-
Page/Page column 28, (2010/11/28)
The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.
O-Arylmandelic acids as highly selective human PPAR α/γ agonists
Adams, Alan D.,Hu, Zao,Von Langen, Derek,Dadiz, Adonis,Elbrecht, Alex,MacNaul, Karen L.,Berger, Joel P.,Zhou, Gaochao,Doebber, Thomas W.,Meurer, Roger,Forrest, Michael J.,Moller, David E.,Jones, A. Brian
, p. 3185 - 3190 (2007/10/03)
A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in